Sörensen et al. [43] performed a phase I clinical trial of the HER2-binding peptide molecule ABY025 labelled with 68Ga for PET to investigate the safety, biodistribution, pharmacokinetics, effect of two peptide masses, and correlation of uptake in tumours with immunohistochemistry. Here, ERBB2 is linked to neoplasm.